Veklury (Remdesivir) retained antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
On Feb. 10, 2022, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness…
On Feb. 9, 2022, the Indiana Department of Health confirmed that a case of H5N1 highly pathogenic avian…
On Feb. 8, 2022, Merck and Ridgeback Biotherapeutics announced that a total of 3.1 million courses of molnupiravir,…
On Feb. 8, 2022, a research team led at Boston University School of Public Health reported on links…
On Feb. 8, 2022, researchers at Oxford University announced they had implanted a novel closed-loop research platform for…
On Feb. 7, 2022, researchers at Washington University School of Medicine in St. Louis announced an analysis of…
On Feb. 3, 2022, T2 Biosystems announced that its T2SARS-CoV-2 Panel detected Omicron COVID-19 subvariants BA.1, BA.2, and…
On Feb. 2, 2022, NIAID scientists announced the new Pandemic Preparedness Plan aimed to support critical basic and…
On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…
On Feb. 2, 2022, President Biden announced a reignition of the Cancer Moonshot, that highlighted new goals: to…
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for…
On Jan. 24, 2022, Pfizer and BioNTech announced the publication of new results from two laboratory studies demonstrating…
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health found that giving peanut…
On Jan. 14, 2022, the U.S. Department of Agricultureï¾’s National Veterinary Services Laboratories confirmed a highly pathogenic Eurasian…
On Jan. 14, 2022, the U.S. Department of Defense, in coordination with the U.S. Department of Health and…
On Jan. 12, 2022, Pfizer announced positive top-line results from a Phase 3 study describing the safety and…
On Dec. 29, 2021, the Department of Defense (DoD), on behalf of and in coordination with the U.S….
On Dec. 28, 2021, Pacific Biosciences announced that its new HiFiViral SARS-CoV-2 solution had successfully sequenced and captured…
On Dec. 28, 2021, researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland announced…
On Dec. 27, 2021, Sorrento Therapeutics announced that initial testing of COVISTIX on recombinant N proteins demonstrated its…
On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) had…
On Dec. 23, 2021, Pfizer and BioNTech announced that they had submitted longer-term follow-up data from the companiesï¾’…
On Dec. 22, 2021, Cocrystal Pharma announced that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main…
On Dec. 22, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…
On Dec. 21, 2021, the University of Oxford’s vaccine manufacturing research team published a pre-print paper demonstrating the…
On Dec. 20, 2021, Pfizer and BioNTech announced an agreement had been reached with the European Commission (EC)…
On Dec. 16, 2021, the Ebola outbreak that erupted in the Democratic Republic of the Congo’s North Kivu…